Novartis AG
NVSEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $11,939,000 | $9,145,180 | $6,955,000 | $24,018,000 |
| Dep. & Amort. | $6,069,000 | $8,277,000 | $7,181,000 | $6,113,000 |
| Deferred Tax | $1,701,000 | $551,000 | $1,416,000 | $2,119,000 |
| Stock-Based Comp. | $1,044,000 | $865,000 | $791,000 | $700,000 |
| Change in WC | -$706,000 | -$369,000 | -$1,003,000 | $241,000 |
| Other Non-Cash | -$2,428,000 | -$4,011,180 | -$1,136,000 | -$18,156,000 |
| Operating Cash Flow | $17,619,000 | $14,458,000 | $14,236,000 | $15,071,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,366,000 | -$2,938,455 | -$2,671,000 | -$2,971,000 |
| Net Acquisitions | -$3,921,000 | -$3,544,718 | -$903,000 | $20,102,000 |
| Inv. Purchases | -$3,547,109 | -$747,000 | -$34,816,000 | -$16,594,000 |
| Inv. Sales/Matur. | $3,701,000 | $11,596,000 | $39,490,000 | $2,740,000 |
| Other Inv. Act. | -$2,379,891 | $1,230,173 | $368,000 | $931,000 |
| Investing Cash Flow | -$7,513,000 | $5,596,000 | $1,468,000 | $4,208,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $4,390,000 | -$1,789,970 | -$2,399,212 | -$2,440,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$8,331,000 | -$8,719,000 | -$10,652,000 | -$3,057,000 |
| Dividends Paid | -$7,624,000 | -$7,255,000 | -$7,752,252 | -$7,383,675 |
| Other Fin. Act. | -$177,000 | $3,485,970 | -$4,788 | -$3,399,000 |
| Financing Cash Flow | -$11,742,000 | -$14,278,000 | -$20,562,000 | -$16,264,000 |
| Forex Effect | -$298,000 | $100,000 | -$32,000 | -$266,000 |
| Net Chg. in Cash | -$1,934,000 | $5,876,000 | -$4,890,000 | $2,749,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $13,393,000 | $7,517,000 | $12,407,000 | $9,658,000 |
| End Cash | $11,459,000 | $13,393,000 | $7,517,000 | $12,407,000 |
| Free Cash Flow | $13,805,000 | $11,705,000 | $11,565,000 | $12,100,000 |